DE69831673D1 - Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme - Google Patents
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahmeInfo
- Publication number
- DE69831673D1 DE69831673D1 DE69831673T DE69831673T DE69831673D1 DE 69831673 D1 DE69831673 D1 DE 69831673D1 DE 69831673 T DE69831673 T DE 69831673T DE 69831673 T DE69831673 T DE 69831673T DE 69831673 D1 DE69831673 D1 DE 69831673D1
- Authority
- DE
- Germany
- Prior art keywords
- exedines
- antagonists
- food consumption
- reduce food
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3490597P | 1997-01-07 | 1997-01-07 | |
US34905P | 1997-01-07 | ||
US5540497P | 1997-08-08 | 1997-08-08 | |
US55404P | 1997-08-08 | ||
US6544297P | 1997-11-14 | 1997-11-14 | |
US6602997P | 1997-11-14 | 1997-11-14 | |
US66029P | 1997-11-14 | ||
US65442P | 1997-11-14 | ||
PCT/US1998/000449 WO1998030231A1 (en) | 1997-01-07 | 1998-01-07 | Use of exendins and agonists thereof for the reduction of food intake |
Publications (3)
Publication Number | Publication Date |
---|---|
DE69831673D1 true DE69831673D1 (de) | 2005-10-27 |
DE69831673T2 DE69831673T2 (de) | 2006-06-22 |
DE69831673C5 DE69831673C5 (de) | 2015-01-22 |
Family
ID=27488253
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE122007000044C Active DE122007000044I2 (de) | 1997-01-07 | 1998-01-07 | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
DE69831673.8T Expired - Lifetime DE69831673C5 (de) | 1997-01-07 | 1998-01-07 | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE122007000044C Active DE122007000044I2 (de) | 1997-01-07 | 1998-01-07 | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
Country Status (16)
Country | Link |
---|---|
US (10) | US6956026B2 (de) |
EP (2) | EP1629849B2 (de) |
JP (1) | JP4798814B2 (de) |
AT (1) | ATE304864T1 (de) |
AU (1) | AU739020B2 (de) |
BE (1) | BE2007C038I2 (de) |
CA (1) | CA2277112C (de) |
DE (2) | DE122007000044I2 (de) |
DK (2) | DK0996459T3 (de) |
ES (2) | ES2247676T3 (de) |
FR (1) | FR07C0031I2 (de) |
HK (1) | HK1025252A1 (de) |
LU (1) | LU91342I2 (de) |
NL (1) | NL300281I2 (de) |
PT (1) | PT1629849E (de) |
WO (1) | WO1998030231A1 (de) |
Families Citing this family (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6767887B1 (en) * | 1996-06-05 | 2004-07-27 | Roche Diagnostics Gmbh | Exendin analogues, processes for their preparation and medicaments containing them |
EP0966297B2 (de) * | 1996-08-08 | 2013-02-27 | Amylin Pharmaceuticals, Inc. | Regulation gastrointestinaler beweglichkeit |
ATE366584T1 (de) * | 1996-11-12 | 2007-08-15 | Novo Nordisk As | Verwendung von glp-1 peptiden |
DE122007000044I2 (de) | 1997-01-07 | 2011-05-05 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
US20040022807A1 (en) * | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
US7910548B2 (en) * | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
EP1938831A1 (de) * | 1997-08-08 | 2008-07-02 | Amylin Pharmaceuticals, Inc. | Neue Exendinagonist-Verbindungen |
DK1019077T4 (da) * | 1997-08-08 | 2011-03-07 | Amylin Pharmaceuticals Inc | Hidtil ukendte exendinagonistforbindelser |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
AU2003200129B2 (en) * | 1997-11-14 | 2006-06-22 | Amylin Pharmaceuticals, Llc | Novel Exendin Agonist Compounds |
AU2006225176B2 (en) * | 1997-11-14 | 2009-01-08 | Amylin Pharmaceuticals, Llc | Novel exendin agonist compounds |
US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
US7223725B1 (en) * | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
EP1938830A1 (de) * | 1997-11-14 | 2008-07-02 | Amylin Pharmaceuticals, Inc. | Neue Exendinagonist-Verbindungen |
NZ504258A (en) | 1997-11-14 | 2002-12-20 | Amylin Pharmaceuticals Inc | Exendin 3 and 4 agonist compounds for the treatment of diabetes |
DK1032587T4 (da) * | 1997-11-14 | 2013-04-08 | Amylin Pharmaceuticals Llc | Hidtil ukendte exendinagonist-forbindelser |
EP1941900A1 (de) * | 1997-11-14 | 2008-07-09 | Amylin Pharmaceuticals, Inc. | Neue Exendinagonist-Verbindungen |
US6998387B1 (en) | 1998-03-19 | 2006-02-14 | Amylin Pharmaceuticals, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
US6284725B1 (en) * | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
US6429197B1 (en) | 1998-10-08 | 2002-08-06 | Bionebraska, Inc. | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
CN100425284C (zh) * | 1999-01-14 | 2008-10-15 | 安米林药品公司 | 抑制胰高血糖素的方法 |
US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
CA2356706C (en) | 1999-01-14 | 2014-09-30 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist formulations and methods of administration thereof |
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
JP2002544127A (ja) | 1999-04-30 | 2002-12-24 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 修飾されたエキセンジンおよびエキセンジン・アゴニスト |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
EP1076066A1 (de) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptide zur Senkung des Blutglukosespiegels |
ES2227115T5 (es) * | 2000-01-10 | 2014-10-30 | Amylin Pharmaceuticals, Inc. | Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia |
ATE309818T1 (de) * | 2000-03-08 | 2005-12-15 | Novo Nordisk As | Senkung des serum cholesterols |
JP2004515533A (ja) | 2000-12-14 | 2004-05-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 代謝障害を治療するためのペプチドyyおよびペプチドyyアゴニスト |
US20090281032A1 (en) * | 2001-03-01 | 2009-11-12 | Peter Raymond Flatt | Modified CCK peptides |
EP2275117B1 (de) | 2001-07-31 | 2016-10-26 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
ATE419863T1 (de) * | 2001-09-24 | 2009-01-15 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
EP1461069A2 (de) * | 2001-12-29 | 2004-09-29 | Novo Nordisk A/S | Kombinierte verwendung einer glp-1-verbindung und eines anderes medikaments zur behandlungv on dyslipidämie |
NZ534557A (en) * | 2002-01-08 | 2007-10-26 | Amylin Pharmaceuticals Inc | Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels |
WO2003057235A2 (en) * | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Modification of feeding behavior |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
EP2028192A1 (de) | 2002-07-04 | 2009-02-25 | Zealand Pharma A/S | GLP-1 und Verfahren zur Diabetesbehandlung |
EP1546200A2 (de) | 2002-10-02 | 2005-06-29 | Zealand Pharma A/S | Stabilisierte exendin-4-verbindungen |
AU2003277446A1 (en) * | 2002-10-17 | 2004-05-04 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
ES2320754T3 (es) * | 2002-10-22 | 2009-05-28 | Waratah Pharmaceuticals, Inc. | Tratamiento de la diabetes. |
EP1569682A2 (de) * | 2002-12-03 | 2005-09-07 | Novo Nordisk A/S | Kombinationsbehandlung mit exendin-4 undthiazolidindionen |
AU2003256988A1 (en) * | 2002-12-11 | 2004-06-30 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
EP1631308B1 (de) * | 2003-05-30 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Neue verfahren und zusammensetzungen für die verbesserte transmukosale abgabe von peptiden und proteinen |
WO2005021026A2 (en) * | 2003-08-29 | 2005-03-10 | Amylin Pharmaceuticals, Inc. | Methods for treating or ameliorating ghrelin-associated diseases and disorders |
ATE525083T1 (de) * | 2003-11-13 | 2011-10-15 | Novo Nordisk As | Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung |
US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
PL3300721T3 (pl) | 2003-11-20 | 2019-08-30 | Novo Nordisk A/S | Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania |
JP4865565B2 (ja) * | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストを用いた食物選択の制御 |
CA2555877C (en) * | 2004-02-11 | 2015-11-24 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2006083254A1 (en) | 2004-02-11 | 2006-08-10 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
BRPI0510117A (pt) | 2004-04-23 | 2007-09-25 | Conjuchem Biotechnologies Inc | método para purificação de conjugados de albumina |
US20090069226A1 (en) * | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
CN1950078A (zh) * | 2004-06-11 | 2007-04-18 | 诺和诺德公司 | 使用glp-1激动剂抵抗药物诱发的肥胖 |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
AU2005305036B2 (en) * | 2004-11-01 | 2011-03-10 | Amylin Pharmaceuticals, Llc | Treatment of obesity and related disorders |
WO2006052608A2 (en) * | 2004-11-01 | 2006-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2007055728A1 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2006074051A2 (en) * | 2004-12-30 | 2006-07-13 | Diakine Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
WO2007022123A2 (en) * | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP1853627A2 (de) | 2005-02-11 | 2007-11-14 | Amylin Pharmaceuticals, Inc. | Gip-analog und hybridpolypeptide mit auswählbaren eigenschaften |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
WO2006099288A2 (en) * | 2005-03-11 | 2006-09-21 | Indevus Pharmaceuticals, Inc. | Controlled release formulations of octreotide |
WO2006105527A2 (en) * | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
JP5693817B2 (ja) * | 2005-08-19 | 2015-04-01 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 糖尿病の治療法および体重の減少法 |
US8389472B2 (en) | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
BRPI0617621A2 (pt) | 2005-10-21 | 2011-08-02 | Novartis Ag | combinação de compostos orgánicos |
WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
EP1954383B1 (de) * | 2005-11-29 | 2012-03-07 | Kolon Industries, Inc. | Geflechtverstärkte hohlfaserverbundmembran |
EP1976876A4 (de) * | 2005-12-22 | 2010-01-13 | Conjuchem Biotechnologies Inc | Verfahren zur herstellung von vorgebildeten konjugaten von albumin und einem therapeutischen mittel |
EA200870575A1 (ru) * | 2006-05-26 | 2009-08-28 | Амилин Фармасьютикалз, Инк. | Композиции и способы лечения застойной сердечной недостаточности |
CN101453982B (zh) | 2006-05-30 | 2011-05-04 | 精达制药公司 | 两件式内部通道渗透递送系统流动调节器 |
KR101193722B1 (ko) * | 2006-07-24 | 2013-01-11 | 바이오렉시스 파마슈티칼 코포레이션 | 엑센딘 융합 단백질 |
WO2008019143A2 (en) * | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc | Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition |
US8501693B2 (en) * | 2006-08-04 | 2013-08-06 | Amylin Pharmaceuticals, Llc | Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen |
ES2422864T3 (es) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Sistemas de liberación osmótica y unidades de pistón |
US20100227809A1 (en) * | 2006-08-17 | 2010-09-09 | Wellstat Therapeutics Corporation | Combination treatment for metabolic disorders |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
US20090318353A1 (en) * | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
KR100872304B1 (ko) * | 2006-11-28 | 2008-12-05 | 주식회사 코오롱 | 편물로 보강된 복합 중공사막 |
TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
RU2440097C2 (ru) | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
US20100323955A1 (en) * | 2007-11-14 | 2010-12-23 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
CN102026666B (zh) * | 2007-12-11 | 2013-10-16 | 常山凯捷健生物药物研发(河北)有限公司 | 促胰岛素肽缀合物制剂 |
EP2240155B1 (de) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe |
US20110046071A1 (en) * | 2008-03-05 | 2011-02-24 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer |
US20110263496A1 (en) | 2008-05-21 | 2011-10-27 | Amylin Pharmaceuticals, Inc. | Exendins to lower cholesterol and triglycerides |
JP5536053B2 (ja) * | 2008-06-25 | 2014-07-02 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド. | 離型剤を有するオクトレオチドインプラント |
US8071537B2 (en) | 2008-06-25 | 2011-12-06 | Endo Pharmaceuticals Solutions Inc. | Implantable device for the sustained release of a polypeptide |
EP2303247A4 (de) * | 2008-07-21 | 2012-08-01 | Syneron Medical Ltd | Transdermales system zur verlängerten freisetzung von inkretinen und inkretin-mimetischen peptiden |
KR101760953B1 (ko) | 2008-09-04 | 2017-07-24 | 아밀린 파마슈티칼스, 엘엘씨. | 비-수성 담체를 이용한 서방성 제형물 |
DE102009038210A1 (de) | 2009-08-20 | 2011-03-03 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
DE102008053048A1 (de) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
NZ592283A (en) | 2008-10-17 | 2012-09-28 | Sanofi Aventis Deutschland | Combination of an insulin and the GLP-1 agonist AVE0010 |
DE102008051834A1 (de) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
CN101870728A (zh) | 2009-04-23 | 2010-10-27 | 派格生物医药(苏州)有限公司 | 新型Exendin变体及其缀合物 |
EP2435061A4 (de) | 2009-05-28 | 2013-03-27 | Amylin Pharmaceuticals Inc | Schlaffördernde glp-1-rezeptor-agonistenverbindungen |
EP3323423B1 (de) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel |
US20120294855A1 (en) * | 2009-11-03 | 2012-11-22 | Eli Lilly & Company | Glp-1 receptor agonist compounds for obstructive sleep apnea |
MX2012005184A (es) | 2009-11-13 | 2012-06-08 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1 y metionina. |
MX2012005186A (es) | 2009-11-13 | 2012-06-08 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina. |
DE102010011919A1 (de) | 2010-03-18 | 2011-09-22 | Sanofi-Aventis Deutschland Gmbh | Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin |
EP2504019A2 (de) | 2009-11-25 | 2012-10-03 | ArisGen SA | Zusammensetzung zur verabreichung über die schleimhaut mit einem komplex aus einem peptid und einer kronenverbindung und/oder einem gegenion |
CN102100912B (zh) * | 2009-12-16 | 2015-04-22 | 上海蓝心医药科技有限公司 | 一种给药组合物及其制备和使用方法 |
WO2011123943A1 (en) | 2010-04-09 | 2011-10-13 | Mount Sinai Hospital | Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist |
JP5969461B2 (ja) | 2010-04-27 | 2016-08-17 | ジーランド ファーマ アクティーゼルスカブ | Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用 |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012050923A2 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action |
WO2012088157A2 (en) | 2010-12-22 | 2012-06-28 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonists for islet cell transplantation |
CA2824143C (en) | 2011-01-14 | 2018-12-18 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US20140221282A1 (en) | 2011-05-25 | 2014-08-07 | Astrazeneca Pharmaceuticals Lp | Long duration dual hormone conjugates |
PT2713722T (pt) | 2011-05-31 | 2017-06-27 | Receptos Llc | Novos estabilizadores e moduladores do receptor glp-1 |
WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
US9382304B2 (en) | 2011-07-08 | 2016-07-05 | Amylin Pharmaceuticals, Llc | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
SI2750699T1 (sl) | 2011-08-29 | 2015-11-30 | Sanofi-Aventis Deutschland Gmbh | Farmacevtska kombinacija, za uporabo pri glikemični kontroli pri pacientih, ki imajo sladkorno bolezen tipa 2 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
EP2763691A1 (de) | 2011-10-04 | 2014-08-13 | Sanofi-Aventis Deutschland GmbH | Glp-1-agonist zur verwendung bei der behandlung von stenose und/oder verstopfungen im pankreasgangsystem |
SI2763690T1 (sl) | 2011-10-04 | 2016-03-31 | Sanofi-Aventis Deutschland Gmbh | Liksisenatid za uporabo pri zdravljenju stenoze in/ali obstrukcije v sistemu vodov trebušne slinavke |
TW201326194A (zh) | 2011-11-03 | 2013-07-01 | Zealand Pharma As | Glp-1胃泌素受體促效劑肽結合物 |
ES2836973T3 (es) | 2011-12-12 | 2021-06-28 | Receptos Llc | Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes |
CA2875743A1 (en) | 2012-06-14 | 2013-12-19 | Sanofi | Exendin-4 peptide analogues |
ES2620111T3 (es) | 2012-07-23 | 2017-06-27 | Zealand Pharma A/S | Análogos de glucagón |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
PL2934567T3 (pl) | 2012-12-21 | 2018-10-31 | Sanofi | Pochodne eksendyny-4 jako podwójny agonista GLP1/GIP lub potrójny agonista GLP1/GIP/glukagon |
KR101581497B1 (ko) | 2013-01-24 | 2015-12-30 | 강원대학교산학협력단 | 인삼열매 추출물을 포함하는 파킨슨병과 알츠하이머병의 예방 또는 치료용 조성물 |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
MX364911B (es) | 2013-03-01 | 2019-05-13 | Fundacio Hospital Univ Vall Dhebron Institut De Recerca | Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial. |
CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
JP6573604B2 (ja) | 2013-06-11 | 2019-09-11 | セルジーン インターナショナル ツー エスエーアールエル | 新規なglp−1レセプターモジュレーター |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
DK3057984T3 (en) | 2013-10-17 | 2018-10-08 | Zealand Pharma As | ACYLED GLUCAGON ANALOGS |
JP2016535770A (ja) | 2013-11-01 | 2016-11-17 | スフェリウム バイオメッド エス.エル. | 治療用及び美容用物質を経皮送達するための封入体 |
US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
EP3080149A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Duale glp-1-/glucagon-rezeptoragonisten |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3091995B1 (de) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilisierte pharmazeutische formulierungen von insulin aspart |
CN114939156A (zh) | 2014-01-09 | 2022-08-26 | 赛诺菲 | 门冬胰岛素的稳定化药物制剂 |
US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AU2015292356B2 (en) | 2014-07-25 | 2020-02-06 | Receptos Llc | Novel GLP-1 receptor modulators |
RU2573933C1 (ru) | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
BR112017008659A2 (pt) | 2014-10-29 | 2018-01-30 | Zealand Pharma As | ?métodos e compostos de agonista de gip? |
ES2844573T3 (es) | 2014-12-10 | 2021-07-22 | Receptos Llc | Moduladores del receptor de GLP-1 |
JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン/リキシセナチド固定比処方 |
EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
HUE055728T2 (hu) | 2015-05-22 | 2021-12-28 | Univ Leland Stanford Junior | Posztbariatrikus hipoglikémia kezelése exendin(9-39)-el |
EP3302354B1 (de) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Systeme zum einsetzen eines implantats |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
WO2017058482A1 (en) * | 2015-10-01 | 2017-04-06 | Schlumberger Technology Corporation | Active damping for nmr logging tools |
CA3001065A1 (en) | 2015-10-14 | 2017-04-20 | Xiaoxi WEI | Compositions and methods for reducing ice crystal formation |
MX2018007859A (es) | 2015-12-23 | 2018-11-09 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1. |
US10653753B2 (en) | 2016-03-04 | 2020-05-19 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
WO2017181007A1 (en) * | 2016-04-15 | 2017-10-19 | Robert Doyle | Peptide drug improvement using vitamin b12 and haptocorrin binding substrate conjugates |
US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
WO2018057977A1 (en) | 2016-09-23 | 2018-03-29 | Delpor, Inc. | Stable compositions for incretin mimetic compounds |
US20180134667A1 (en) | 2016-10-14 | 2018-05-17 | TES Pharma S.r.I. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
JP2019535734A (ja) | 2016-11-21 | 2019-12-12 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドEiger Biopharmaceuticals, Inc. | エキセンディン(9−39)の緩衝製剤 |
EP3551202B1 (de) | 2016-12-06 | 2024-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren zur erhöhung der wirksamkeit von incretinbasierten arzneimitteln bei darauf angewiesenen personen |
EP3551651B1 (de) | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Acylierte glp-1/glp-2 duale agoniste |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
KR20200019122A (ko) | 2017-06-20 | 2020-02-21 | 암젠 인크 | Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법 |
PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
AU2019250359A1 (en) | 2018-04-10 | 2020-11-26 | Sanofi-Aventis Deutschland Gmbh | Method for cleavage of solid phase-bound peptides from the solid phase |
US11028123B2 (en) | 2018-04-10 | 2021-06-08 | Sanofi-Aventis Deutschland Gmbh | Capping of unprotected amino groups during peptide synthesis |
MX2021005904A (es) | 2018-11-20 | 2021-09-08 | Tes Pharma S R L | Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa. |
EP3934679A1 (de) | 2019-03-08 | 2022-01-12 | Amgen Inc. | Kombinationstherapie mit wachstumsdifferenzierungsfaktor 15 |
EP4106724A1 (de) | 2020-02-18 | 2022-12-28 | Novo Nordisk A/S | Glp-1-zusammensetzungen und verwendungen davon |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5175145A (en) * | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
WO1990011296A1 (en) | 1989-03-20 | 1990-10-04 | The General Hospital Corporation | Insulinotropic hormone |
ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5187154A (en) * | 1990-12-13 | 1993-02-16 | Board Of Regents, The University Of Texas System | Diagnosis and treatment of humans with diabetes or at risk to develop diabetes |
US5264372A (en) * | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
HU222249B1 (hu) * | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
SK155694A3 (en) | 1992-06-15 | 1995-05-10 | Pfizer | Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5424289A (en) * | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
RU2177331C2 (ru) | 1993-09-07 | 2001-12-27 | Амилин Фармасьютикалз, Инк. | Способы регулирования моторики желудочно-кишечного тракта |
WO1995007089A1 (en) | 1993-09-09 | 1995-03-16 | Imutec Corporation | Immunomodulating compositions from bile |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
JPH10511077A (ja) * | 1994-08-26 | 1998-10-27 | ナンシー、 エム. リー、 | N末端基で切断されたダイノルフィン類似体を用いた鎮痛方法 |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5641425A (en) * | 1994-09-08 | 1997-06-24 | Multiform Desiccants, Inc. | Oxygen absorbing composition |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
WO1997002004A2 (en) * | 1995-06-30 | 1997-01-23 | Eli Lilly And Company | Methods for treating diabetes |
SE504450C2 (sv) | 1996-02-19 | 1997-02-17 | Kavlugnt Ab | Kopplingsanordning för sammankoppling av ett arbetsredskap till en arbetsmaskin; både mekanisk hopkoppling och snabbkoppling av hydraullikkopplingarna |
US6767887B1 (en) * | 1996-06-05 | 2004-07-27 | Roche Diagnostics Gmbh | Exendin analogues, processes for their preparation and medicaments containing them |
US5686511A (en) | 1996-06-28 | 1997-11-11 | The Valspar Corporation | Esterifying epoxy resin with carboxyl polymer and quenching |
EP0930882A2 (de) | 1996-08-02 | 1999-07-28 | Institut Pasteur De Lille | Vorbeugung oder behandlung von typ 2 diabetes oder kardiovaskulärer erkrankung mit ppar modulatoren |
EP0966297B2 (de) | 1996-08-08 | 2013-02-27 | Amylin Pharmaceuticals, Inc. | Regulation gastrointestinaler beweglichkeit |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
US5677279A (en) * | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
DE122007000044I2 (de) | 1997-01-07 | 2011-05-05 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
US5830904A (en) * | 1997-02-05 | 1998-11-03 | University Of Kentucky Research Foundation | Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders |
US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
US7910548B2 (en) * | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
DK1019077T4 (da) | 1997-08-08 | 2011-03-07 | Amylin Pharmaceuticals Inc | Hidtil ukendte exendinagonistforbindelser |
HUP0100349A3 (en) | 1997-12-12 | 2002-02-28 | Warner Lambert Co | Pharmaceutical compositions containing antihyperlipidemic statin-lp(a) inhibitor |
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
US6783942B2 (en) * | 1998-10-08 | 2004-08-31 | Uab Research Foundation | Isolated polynucleotide associated with type II diabetes mellitus and methods of use thereof |
US6326396B1 (en) * | 1998-11-20 | 2001-12-04 | Alteon, Inc. | Glucose and lipid lowering compounds |
CA2356706C (en) * | 1999-01-14 | 2014-09-30 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist formulations and methods of administration thereof |
US6153432A (en) * | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
JP2002544127A (ja) | 1999-04-30 | 2002-12-24 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 修飾されたエキセンジンおよびエキセンジン・アゴニスト |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
ES2227115T5 (es) * | 2000-01-10 | 2014-10-30 | Amylin Pharmaceuticals, Inc. | Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia |
US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
US7232798B2 (en) * | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
-
1998
- 1998-01-07 DE DE122007000044C patent/DE122007000044I2/de active Active
- 1998-01-07 EP EP05011978.3A patent/EP1629849B2/de not_active Expired - Lifetime
- 1998-01-07 ES ES98904545T patent/ES2247676T3/es not_active Expired - Lifetime
- 1998-01-07 DE DE69831673.8T patent/DE69831673C5/de not_active Expired - Lifetime
- 1998-01-07 PT PT50119783T patent/PT1629849E/pt unknown
- 1998-01-07 CA CA002277112A patent/CA2277112C/en not_active Expired - Lifetime
- 1998-01-07 EP EP98904545A patent/EP0996459B1/de not_active Expired - Lifetime
- 1998-01-07 DK DK98904545T patent/DK0996459T3/da active
- 1998-01-07 WO PCT/US1998/000449 patent/WO1998030231A1/en active IP Right Grant
- 1998-01-07 US US09/003,869 patent/US6956026B2/en not_active Expired - Lifetime
- 1998-01-07 AT AT98904545T patent/ATE304864T1/de active
- 1998-01-07 ES ES05011978.3T patent/ES2425559T5/es not_active Expired - Lifetime
- 1998-01-07 DK DK05011978.3T patent/DK1629849T4/en active
- 1998-01-07 AU AU62394/98A patent/AU739020B2/en not_active Expired
- 1998-01-07 JP JP53114798A patent/JP4798814B2/ja not_active Expired - Lifetime
-
2000
- 2000-07-21 HK HK00104513A patent/HK1025252A1/xx not_active IP Right Cessation
-
2002
- 2002-06-28 US US10/187,051 patent/US6989366B2/en not_active Expired - Fee Related
-
2004
- 2004-07-19 US US10/894,999 patent/US7297761B2/en not_active Expired - Fee Related
- 2004-07-20 US US10/895,909 patent/US7741269B2/en not_active Expired - Fee Related
- 2004-10-14 US US10/966,337 patent/US7138375B2/en not_active Expired - Fee Related
- 2004-10-15 US US10/964,887 patent/US7115569B2/en not_active Expired - Fee Related
-
2006
- 2006-03-03 US US11/368,225 patent/US7419952B2/en not_active Expired - Fee Related
-
2007
- 2007-05-16 BE BE2007C038C patent/BE2007C038I2/fr unknown
- 2007-05-16 FR FR07C0031C patent/FR07C0031I2/fr active Active
- 2007-05-18 LU LU91342C patent/LU91342I2/fr unknown
- 2007-05-18 NL NL300281C patent/NL300281I2/nl unknown
-
2008
- 2008-08-29 US US12/201,918 patent/US7700549B2/en not_active Expired - Fee Related
-
2010
- 2010-04-23 US US12/766,195 patent/US8288338B2/en not_active Expired - Fee Related
-
2012
- 2012-09-14 US US13/618,922 patent/US20130023470A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69831673D1 (de) | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme | |
DE59601122D1 (de) | N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten | |
FI941500A (fi) | Hormonianalogit joissa on moninkertaisia CTP-lisäkkeitä | |
DE60015082D1 (de) | Künstliche peptide mit oberflächenaktivität und ihre verwendung zur herstellung von künstlichen tensiden | |
ATE311762T1 (de) | Verwendung von säurestabilen subtilisinproteasen in tierfutter | |
ATE107130T1 (de) | Zusammensetzung und ihre verwendung. | |
NO954188D0 (no) | Modifisert-protein- og -peptid - farmasöytika | |
DE68903576T2 (de) | Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen. | |
DE68903255T2 (de) | Sieb zur reinigung und klassifizierung von papierstoffbrei. | |
DE69811080D1 (de) | Anwendung von dihydroxychinolinverbindungen zur verlängerung der haltbarkeit von säugetier- und fischprodukten | |
FI953640A0 (fi) | Termostabiilit ksylanaasi-DNA, proteiini ja käyttömenetelmät | |
DE69621146T2 (de) | Verwendung von Galactanase in Tierfutter | |
DE69103112D1 (de) | Nahrungsmittelzusammensetzung mit hohem Proteingehalt und hoher Viskosität. | |
ATE109950T1 (de) | Verwendung von geschützten aminosäuren in futtermitteln für schafe. | |
DE69801515D1 (de) | Herstellung von aluminiumhydroxid mit getrennter kontrolle des natriumgehalts und der korngrösse | |
PL337507A1 (en) | Novel derivatives of beta-amino and beta-azidocarboxylic acids, their production and application as antagonists of endothelin receptors | |
DE58906436D1 (de) | Konzentrierte und flüssige wasserhaltige Tensidzusammensetzung und deren Verwendung. | |
IS5408A (is) | Samsetning valvísra 5-HT1A mótlyfja og valvíss h5-HT1B mótlyfs eða gerandefnis með hlutaverkun | |
ATE83395T1 (de) | Katalytische zusammensetzung und deren verwendung zur oligomerisation von monoolefinen. | |
DE69717508D1 (de) | Amphiphile perfluoroalkyl-modifizierte polydiene und ihre verwendung in der bearbeitung von leder | |
ATE412744T1 (de) | Polypeptid-tag's für den nachweis und die aufreinigung von polypeptiden | |
DE29721947U1 (de) | Kontrollinstrument zur Feststellung der Kosten von Besprechungen und Konferenzen | |
ITTO910676A0 (it) | Perfezionamenti nella calcinazione dell'allumina. | |
ATE98519T1 (de) | Konzentrierte und fluessige wasserhaltige tensidzusammensetzung und deren verwendung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R431 | Request for term correction |
Free format text: PRODUCT NAME: EXENATIDE; REGISTRATION NO/DATE: EU/1/06/362/001-004 20061120 Spc suppl protection certif: 122007000044 Filing date: 20070518 Expiry date: 20180108 Extension date: 20211122 |
|
R432 | Decision on term correction now final |
Free format text: PRODUCT NAME: EXENATIDE; REGISTRATION NO/DATE: EU/1/06/362/001-004 20061120 Spc suppl protection certif: 122007000044 Filing date: 20070518 Expiry date: 20180108 Extension date: 20211122 |